国际妇产科学杂志

国际妇产科学杂志 ›› 2013, Vol. 40 ›› Issue (1): 93-96.

• 论著 • 上一篇    下一篇

G蛋白耦联受体30和表皮生长因子受体在子宫内膜腺癌中的表达

朱其舟, 舒宽勇   

  1. 330006 南昌,江西省妇幼保健院
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2013-02-15 发布日期:2013-02-15
  • 通讯作者: 舒宽勇

Expression and Correlation of GPR30 and EGFR in Endometrial Adenocarcinoma and Its Clinical Significance

ZHU Qi-zhou，SHU Kuan-yong   

  1. Maternal and Child′s Healthcare Hospital of Jiangxi Province，Nanchang 330006，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2013-02-15 Online:2013-02-15
  • Contact: SHU Kuan-yong

PDF (PC)

5079

摘要： 目的：探讨G蛋白耦联受体30（GPR30）和表皮生长因子受体（EGFR）在子宫内膜腺癌组织中表达的意义及其关系。方法：20例子宫内膜不典型增生（EAH）组织、50例子宫内膜腺癌（EAC）组织，采用免疫组化EliVision二步法检测各组组织中GPR30和EGFR表达情况，另设20例正常子宫内膜组织标本作为对照组。分析GPR30和EGFR的表达与子宫内膜癌患者临床病理特征的关系。结果：对照组、EAH组、EAC组组织中GPR30的阳性表达率分别为10.0%、45.0%和74.0%，组间比较差异有统计学意义（P＜0.001），EAH组显著高于对照组（P＜0.05），EAC组显著高于EAH组（P＜0.05）；GPR30表达与EAC组织病理学分级有关（P＜0.05），但与其他临床病理特征无关（P＞0.05）。EGFR在对照组、EAH和EAC组中阳性表达率分别为30.0%、40.0%和70.0%， EAC组显著高于EAH组和对照组（P＜0.05，P＜0.001），但EAH组与对照组差异无统计学意义（P＞0.05）。在EAC组中，EGFR表达与手术-病理分期、组织病理学分级和肿瘤直径有关（P＜0.05），与其他临床病理参数无关（均P＞0.05）。EAC组中GPR30和EGFR表达呈正相关（r=0.308，P＜0.05）。结论：GPR30和EGFR的过表达可能与子宫内膜腺癌的发生发展相关。GPR30和EGFR在子宫内膜腺癌中表达呈正相关，两者间可能存在相互作用。GPR30和EGFR可能成为治疗子宫内膜癌更为有效的新靶点。

关键词: 子宫内膜肿瘤, 腺癌, 受体, 表皮生长因子, 预后, 免疫组织化学, G蛋白耦联受体30, G蛋白耦联雌激素受体

Abstract: Objective：To explore the expression and clinical significance of G protein-coupled receptor 30（GPR30） during carcinogenesis of endometrium. Methods：The expression of GPR30 and EGFR in 20 cases of endometrial atypical hyperplasia （EAH group） and 50 cases of endometrial carcinoma （EAC group） were detected by immunohistochemical EliVision two stages method. Another 20 cases of normal endometrial tissue specimen were as a control group. Results：In group of control， EAH group and EAC group， the positive rates of GPR30 were 10.0%，45.0% and 74.0%，respectively. The differences among the three groups was statistically significant（P＜0.001），EAH group was significantly higher than the control group（P＜0.05）， and significantly lower than the EAC group（P＜0.05）. In EAC patients， the expression of GPR30 was not associated with age，surgery-pathological stage， depth of myometrial invasion， tumor size and lymph node metastasis（P＞0.05，respectively） but
the type of histology，the expression of GPR30 with different tumor grade showed a significant statistical difference（P＜0.05）.
The expression rates of EGFR in normal endometrium，EAH and EAC tissues were 30.0%， 40.0% and 70.0%， respectively， showing a rising trend. The positive expression rate and expression intensity of EGFR in EAC group was significantly higher than that in EAH group or control group （P＜0.05，P＜0.001， respectively），but the difference of that between EAH group and control group were no statistical significance（P＞0.05）. In the EAC group， EGFR positive expression intensity correlated with FIGO stage， histopathological grade or tumor diameter （P＜0.05，respectively），its expression did not correlate with any other clinicopathological parameters（P＞0.05）. Positively correlation between the expression of GPR30 and that of EGFR was
observed in EAC group （r=0.308，P＜0.05） Conclusions：GPR30 and EGFR probably have relationships with the occurrence and development of endometrial carcinoma. GPR30 and EGFR expression in endometrial adenocarcinoma was positively
correlated with each other， there could be interaction between the two. GPR30 and EGFR could be more effective novel
therapeutic targets of endometrial cancer.

Key words: Endometrial neoplasms, Adenocarcinoma, Receptor, epidermal growth factor, Prognosis, Immunohistochemistry, G protein-coupled estrogen receptor